Tra i New drugs There is one able to help patients ad high cardiovascular riskand significantly reduce cardiovascular events and therefore save. The results of Two new different and large international studiesconducted overall on Over 35 thousand people.
New drugs: semiglutide to manage multiple pathologies
The pill based on traffic lights It reduces 14% heart attack, stroke and mortality from cardiac causes in those with type 2 diabetes and a high cardiovascular risk, while in the formulation Injectively protects the heart of those who have no blood sugar problems but it is overweight or obesedecreasing up to 57% the risk of heart attacks, strokes and deaths.
New drugs, scientific studies presented in Chicago
This is underlined by the results of two international studies presented for the first time at the Congress of‘American College of Cardiology (ACC). According to research, the GLP-1 agonist semaglutide prevents serious cardiovascular events in all high -risk patients in which its use is indicated for the presence of diabetes or obesity.
The first research, of which the definitive results are now available, is the Soul multicenter international study, which involved 9650 people with type 2 diabetes and cardiovascular disease and/or chronic renal failure, treated with oral or placebo traffic lights and followed for 5 years.
How the therapy with trafficlutide works
Semaglutide therapy, the only GLP-1 drug for which the oral formulation is approved, to which in 49% of the participants a SGLT2 inhibitor has been added the risk of heart attack, stroke and death for cardiac causes by 14%.
New drugs and protection for the heart
And as he points out Pasquale Perrone Filardi, president of the Italian Cardiology Society (Sic)«The effect of cardiovascular protection It is clear, as well as independent of any treatment with inhibitory drugs indicated in diabetes therapy (SGLT2). The use of the semaglutide -based pill improves heart health and vases e prevents the progression of atherosclerosis “.
A higher efficacy than any other oral therapy
“This GLP-1 agonist has a higher efficacy than any other oral therapy also in the reduction of the values of glycated hemoglobin and in the weight decrease body. All this translates into a substantial protective action on the cardiovascular system “, specifies the expert.
New drugs, security and tolerability
The Soul study confirmed the safety and tolerability of use of traffic lights and on the basis of the new cardiovascular protection results it was requested from FDA and Hema an extension of the indication of use for the reduction of cardiovascular risk. “We must keep in mind that One person with diabetes in three also has a cardiovascular disease. Therefore it is crucial to have therapies that can affect both conditions – he adds Ciro Polfi, president of the Italian Federation of Cardiology (FIC) -. The mechanism of action and the effects of oral traffic light therefore make this treatment the Gold Standard To intervene promptly on the reduction of cardiovascular risk in people with type 2 diabetes ».
This is also true in those who do not have high blood sugar but have cardiovascular problems and obesity, as demonstrated by the results of the analysis of the data obtained in the real clinical practice during the international study and observational score studio, which was with
I woman © RESERVED REPRODUCTION